CompletedPhase 2

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

United States16 participantsStarted 2020-06-08

Plain-language summary

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * APOL1 genotype of G1/G1, G2/G2, or G1/G2 * FSGS diagnosed by kidney biopsy Key Exclusion Criteria: * Evidence of non-APOL1-mediated FSGS * Participants with known sickle cell disease * Solid organ or Bone marrow transplant Other protocol defined Inclusion/Exclusion criteria may apply.

What they're measuring

Percent Change From Baseline in UPCR

Timeframe: From Baseline up to Week 13

Trial details

NCT IDNCT04340362

SponsorVertex Pharmaceuticals Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-11-11

Results submitted2023-04-28

View on ClinicalTrials.gov More Glomerulosclerosis, Focal Segmental trials